"10.1371_journal.pone.0089789","plos one","2014-03-04T00:00:00Z","Calvin Q Pan; Huy Trinh; Alan Yao; Ho Bae; Lillian Lou; Sing Chan; for the Study 123 Group","Division of Gastroenterology, Department of Medicine, New York University Langone Medical Center, New York University School of Medicine, New York, United States of America; San Jose Gastroenterology, San Jose, California, United States of America; AE & LY Medical Associates, Flushing, New York, United States of America; Asian Pacific Liver Center, St. Vincent Medical Center, Los Angeles, California, United States of America; Nexus Development, Palo Alto, California, United States of America; Sing Chan Endoscopy, Flushing, New York, United States of America","Conceived and designed the experiments: CQP LL. Performed the experiments: CQP HT AY HB SC. Analyzed the data: CQP LL. Wrote the paper: CQP LL HT AY HB SC.","We have the following interests. This study was sponsored by Gilead, the employer of LL at the time of the study. Lillian Lou is employed by Nexus Development. CQP has acted as a consultant or speaker for Gilead Sciences, Genentech, Vertex, Onyx, BMS, and Merck, and has received grants from Gilead Sciences, Roche, BMS, and Vertex. HT has acted as a speaker and advisory board member, and has received research grants from Gilead Sciences and BMS, and owns stock in Gilead Sciences. AY has acted as a speaker for Gilead Sciences and BMS. HB hs acted as a speaker for Gilead Sciences, BMS, and Genentech. SC has acted as a speaker for Gilead Sciences, and owns no more than $20K worth of Gilead stock. Tenofovir disoproxil fumarate is a product of Gilead Sciences. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","03","Calvin Q Pan","CQP",7,TRUE,2,5,2,6,TRUE,TRUE,TRUE,1,"7",TRUE
